Drug Trial Radar · NCT05413122
Evaluating Smoking Cessation Interventions for PWH in South Africa
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
660
Planned (sponsor's estimate)
Start
Nov 27, 2023
Primary completion
Aug 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Colorado State University; New York University; Perinatal HIV Research Unit of the University of the Witswatersrand; National Cancer Institute (NCI)
- First posted
- Jun 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of the study is to optimize a smoking cessation treatment package for people with HIV (PWH) that can be integrated into existing HIV care in South Africa.
Conditions
- Smoking Cessation
- HIV
- Comorbidities and Coexisting Conditions
Interventions
VareniclineDrug
At enrolment, a 12-week course of varenicline in the commercially available package will be dispensed by a study clinician.
Nicotine patchDrug
A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
Nicotine gumDrug
A 12-week course of nicotine patches and nicotine gum will be dispensed to the participant by the counsellor according to randomization into the c-NRT condition. c-NRT will be provided per label instructions given number of cigarettes the participant smokes per day and will be provided in the commercially available package.
Intensive Behavioral CounsellingBehavioral
Participants randomized to the Intensive Behavioural Counselling condition will receive in-person intensive (\~45 minutes) behavioural counselling in the clinic at screening and at weeks 2, 4, 8, and 12. Additionally, on non-clinic visit weeks participants will receive (1) one phone call each week from the clinic counsellor, and (2) two text messages each week providing encouragement and advice.
Peer CounsellingBehavioral
Participants randomized to the Peer Support condition will be engaged by a peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 7-day point prevalence tobacco abstinence at 52 weeksTime frame: 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Perinatal HIV Research Unit (PHRU)
Soweto, Gauteng, South Africa · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.